# Sample Aesthetics â€” France vs Benelux Commercial Performance

<div align="center">

[![Sample Aesthetics](https://img.shields.io/badge/Sample_Aesthetics-Performance_Analysis-B87333?style=for-the-badge)](#)
[![Analysis Period](https://img.shields.io/badge/Period-36_Months-F5EFE6?style=for-the-badge)](#)
[![Status](https://img.shields.io/badge/Status-Insight_Ready-success?style=for-the-badge)](#)

**Identifying â‚¬148K+ annual revenue opportunity through targeting optimization**

*Visual design inspired by Allergan Aesthetics brand guidelines*

</div>

---

## Client Background

**Sample Aesthetics** operates across France and Benelux (Belgium, Netherlands, Luxembourg) with a focused portfolio of facial injectables, dermal fillers, and skincare products.  
Over 36 months (Nov 2022â€“Oct 2025), the company generated â‚¬20.8M through 641 clinics served by 51 sales representatives. Despite similar coverage rates, France outperforms Benelux by 4.3x in absolute revenueâ€”revealing a targeting quality issue, not an effort problem.

### North Star Metrics
- **Coverage & Frequency**: Visits per clinic and call plan compliance  
- **Conversion Quality**: Revenue per rep visit (â‚¬1,186 France vs â‚¬467 Benelux)  
- **Market Share**: Units sold vs estimated competitor activity  
- **Rep Productivity**: Visit-to-revenue correlation (lagged)  
- **Territory Opportunity**: Clinic potential score vs realized revenue  

---

## Executive Summary

### The Bottom Line

France generates â‚¬16.9M (4.3x Benelux) with accelerating momentum (+14% H1â†’H2 growth), while Benelux plateaus at â‚¬3.9M (+7.2% growth).  
**The root cause isn't market sizeâ€”it's targeting precision.** Benelux has 67% coverage (similar to France's 65%), but visits convert at 2.5x lower rates.  
Fix targeting, and we unlock â‚¬148K+ annually with zero new headcount.

<div align="center">
  <img src="./0.png" alt="Visual 0: Overview France vs Benelux" />
</div>

---

## 1. Revenue Trajectory with Regulatory Impact

<div align="center">
  <img src="./1.png" alt="Visual 1: Revenue trajectory" />
</div>

---

## 2. Coverage vs Opportunity: The Targeting Quality Gap

<div align="center">
  <img src="./2.png" alt="Visual 2: Coverage vs Opportunity" />
</div>

---

## 3. Rep Productivity: Visit-to-Revenue Correlation

<div align="center">
  <img src="./3.png" alt="Visual 3: Rep productivity correlation" />
</div>

---

## 4. Promotion Event Study: Diff-in-Diff Analysis

<div align="center">
  <img src="./4.png" alt="Visual 4: Promotions Diff-in-Diff" />
</div>

---

## 5. Territory Opportunity Mapping & Pilot Design

<div align="center">
  <img src="./5.png" alt="Visual 5: Territory Opportunity Map" />
</div>

---

## 6. Sales Incentive Plan Simulation

<div align="center">
  <img src="./6.png" alt="Visual 6: SIP simulation payout curves" />
</div>

---

## Visual Styling Guide (for Webapp)

**Color Palette**  
- **Copper accent:** `#B87333` â†’ key highlights, KPIs  
- **Pale Peach:** `#F5EFE6` â†’ card backgrounds  
- **Light Tan:** `#DABFAA` â†’ borders, accents  
- **Dark Charcoal:** `#212121` â†’ text, labels  
- **White:** `#FFFFFF` â†’ clean background  

**Typography**  
- **Font:** Helvetica Neue / system sans-serif  
- **Titles:** 24â€“28 px bold  
- **Subheads:** 18â€“20 px medium  
- **Body text:** 12â€“14 px regular  
- **Chart labels:** 10â€“12 px  

**Chart Rules**  
- Use a variety: line, scatter, heatmap, Sankey, event study, and payout curves  
- Copper = hero color  
- Minimize non-data ink; keep legends and axes clear  
- Ensure accessibility and contrast  

---

## Methodology & Caveats

This analysis uses **synthetic but realistic data** seeded with public anchors (ISAPS, DREES, clinic registries).  
All observed patterns mimic plausible commercial performance but do **not** represent real company data.

**Key analytical methods**  
- Growth rates: H1 vs H2 comparisons  
- Lagged regression (visit â†’ revenue +1 month)  
- Diff-in-diff for promo impact  
- Opportunity scoring (30% potential, 50% revenue, 20% growth)  
- Gini fairness metric for incentive models  

**Caveats**  
Correlation â‰  causation.  
Event studies and pilots estimate incremental impact but retain uncertainty.  
Always validate pilots with control groups or A/B tests.

---

## Next Steps

**Next 30 Days**
- âœ… Present insights to Sales Leadership  
- âœ… Launch Benelux pilot (35 clinics, â‚¬148K target)  
- âœ… Validate re-tiering model  
- âœ… Assign pilot reps (4 Netherlands reps)  

**Q1 2026**
- Run pilot with weekly KPI dashboard  
- Start rep coaching (French best practices)  
- Prepare promotional calendar for full 2026  
- Draft SIP Variant C (opportunity-adjusted)

**Q2 2026**
- Review pilot results (+â‚¬37K quarterly incremental)  
- Scale or pivot based on data  
- Deploy SIP Variant C for H2 2026 pilot  

---

<div align="center">

**Built by an analyst who finds money, not just dashboards** ðŸ’Š  

[![Made with Python](https://img.shields.io/badge/Python-Analysis-3776AB?style=flat-square&logo=python&logoColor=white)](#)
[![React](https://img.shields.io/badge/React-Visualizations-61DAFB?style=flat-square&logo=react&logoColor=black)](#)
[![Impact](https://img.shields.io/badge/Impact-â‚¬148K_Identified-B87333?style=flat-square)](#)

**â‚¬148K+ Annual Opportunity | Zero New Headcount | Data-Driven Targeting**

</div>
